Paper40744833
Prostate cancer germline variants with therapeutic implications.
Bitaraf M and 2 others. Trends Mol Med, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Prostate cancer germline variants with therapeutic implications. Papers, record 40744833. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40744833
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Germ-Line Mutation | Major topic |
| Prostatic Neoplasms | Major topic |
| Humans | |
| Male | |
| Genetic Predisposition to Disease | |
| BRCA2 Protein | |
| BRCA1 Protein | |
| Poly(ADP-ribose) Polymerase Inhibitors |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA172382 | NCI NIH HHS | United States | R01CA172382 | PubMed and NIH | NIH RePORTER |
| R01 CA249279 | NCI NIH HHS | United States | R01CA249279 | PubMed and NIH | NIH RePORTER |
| R01 CA261995 | NCI NIH HHS | United States | R01CA261995 | PubMed and NIH | NIH RePORTER |
References94
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27575027 | HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27575027 | PubMed |
| 2 | 32053149 | HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32053149 | PubMed |
| 3 | 39930085 | Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups. | Nat Genet | 2025 | https://conductscience.org/library/papers/39930085 | PubMed |
| 4 | 31237441 | Clinical implications of mismatch repair deficiency in prostate cancer. | Future Oncol | 2019 | https://conductscience.org/library/papers/31237441 | PubMed |
| 5 | 34225539 | Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. | Expert Opin Ther Targets | 2021 | https://conductscience.org/library/papers/34225539 | PubMed |
| 6 | 28706734 | BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. | Integr Cancer Sci Ther | 2017 | https://conductscience.org/library/papers/28706734 | PubMed |
| 7 | 39052257 | BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review. | JAMA Oncol | 2024 | https://conductscience.org/library/papers/39052257 | PubMed |
| 8 | 26455355 | Prostate Single Nucleotide Polymorphism Provides a Crucial Clue to Cancer Aggression in Active Surveillance Patients. | Eur Urol | 2016 | https://conductscience.org/library/papers/26455355 | PubMed |
| 9 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 10 | 27070714 | Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. | Br J Cancer | 2016 | https://conductscience.org/library/papers/27070714 | PubMed |
| 11 | 30589920 | Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/30589920 | PubMed |
| 12 | 23569316 | Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23569316 | PubMed |
| 13 | 29439820 | Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. | Eur Urol | 2018 | https://conductscience.org/library/papers/29439820 | PubMed |
| 14 | 23863050 | Alpha emitter radium-223 and survival in metastatic prostate cancer. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23863050 | PubMed |
| 15 | 37966114 | Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer. | J Clin Invest | 2023 | https://conductscience.org/library/papers/37966114 | PubMed |
| 16 | 32955174 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32955174 | PubMed |
| 17 | 29429804 | Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. | Eur Urol | 2018 | https://conductscience.org/library/papers/29429804 | PubMed |
| 18 | 20534728 | 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. | Endocrinology | 2010 | https://conductscience.org/library/papers/20534728 | PubMed |
| 19 | 37963304 | Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/37963304 | PubMed |
| 20 | 16998501 | The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. | Oncogene | 2006 | https://conductscience.org/library/papers/16998501 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42891338 | A Metabolic Cluster-Derived Risk Model for Prognostic Stratification, Immunometabolic Profiling, and Therapeutic Sensitivity Prediction in Prostate Cancer. | Cancer Manag Res | 2026 | https://conductscience.org/library/papers/42891338 | PubMed |
| 42518214 | 3beta-HSD1-mediated steroid back-conversion maintains androgen signaling in prostate cancer. | Mol Cancer Res | 2026 | https://conductscience.org/library/papers/42518214 | PubMed |
| 41763410 | Serendipity, steroids and science. | J Steroid Biochem Mol Biol | 2026 | https://conductscience.org/library/papers/41763410 | PubMed |
| 41735769 | Androgen metabolism in prostate cancer: recent advances. | Endocrinology | 2026 | https://conductscience.org/library/papers/41735769 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| BRCA2 | 675 | PubTator's text mining | https://conductscience.org/library/genes/675 | NCBI Gene |
| HSD3B1 | 3283 | PubTator's text mining | https://conductscience.org/library/genes/3283 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40744833
GET https://conductscience.org/api/papers/v1/40744833/references?page=2